ANGLE plc signs deal with AstraZeneca to develop Parsortix-based AR detection assay for prostate cancer studies

Pallavi Madhiraju- May 4, 2024 0

In a deal valued at £550,000, ANGLE plc (AIM:AGL, OTCQX:ANPCY), a leading liquid biopsy company specializing in circulating tumor cell (CTC) solutions, has secured an ... Read More

ANGLE plc collaborates with AstraZeneca on cutting-edge cancer detection technology

Pallavi Madhiraju- April 29, 2024 0

ANGLE plc, a leading innovator in liquid biopsy and circulating tumour cell (CTC) solutions, has announced a significant supplier agreement with global biopharmaceutical leader AstraZeneca ... Read More

ANGLE plc announces cancer diagnosis breakthrough with DNA molecular analysis

Pallavi Madhiraju- January 5, 2024 0

ANGLE plc, a global leader in liquid biopsy technology, has recently achieved a major breakthrough in cancer diagnostics, unveiling results from DNA molecular analysis of ... Read More

Liquid biopsy company ANGLE plc bags pharma services contract

pallavi123- April 17, 2021 0

UK-based liquid biopsy company ANGLE plc has won a pharma services contract worth up to $1.2 million from an undisclosed pharma company that is engaged ... Read More